If your product fails a payer test, a workflow test, or a stakeholder-adoption test, delay the big launch budget. Run a one-week readiness sprint first. Market readiness in healthcare rests on six checkable dimensions: customer value, regulatory pathway, reimbursement, evidence, workflow fit, and stakeholder buy-in. Score those honestly before committing real money.
TL;DR:
- A billing code alone does not establish revenue; test clinician eligibility, qualifying data cadence, documentation, consent, and whether a pilot claim gets paid.
- When a predicate device exists, teams may pursue the standard clearance route; De Novo applies without one, while PMA requires extensive clinical evidence.
- Before procurement, prepare plain language model documentation, working FHIR data exchange, and a written maintenance commitment; ONC's HTI-1 rule raises expectations for algorithm transparency.
- A single site pilot can proceed with limited evidence, but wider rollout requires verified integration and outcomes that support the marketed claim.
- Score every readiness dimension red, yellow, or green, and assign an owner; a red regulatory or reimbursement score should halt launch planning.
Table of Contents
- What market readiness means in healthcare
- Core readiness dimensions: a checklistable framework
- Regulatory readiness in the U.S.: classify first, plan next
- Reimbursement and payer readiness: test operational assumptions, not just codes
- Interoperability and algorithm transparency: what buyers expect now
- The Startup MD's rapid market readiness checklist and one-week sprint
- Author perspective: decision rules for go or no-go
- How The Startup MD can help: fractional CMO and advisory services
- FAQ
- Sources
What market readiness means in healthcare
Product readiness asks whether something works. Market readiness asks whether the people who must adopt it will actually say yes: the clinician who has to change a workflow, the payer who has to approve a code, the patient who has to trust the data collection. We define market readiness operationally as the point where value, evidence, regulatory status, reimbursement pathway, and workflow fit are all validated enough to survive contact with real buyers.
Timing matters more than most teams admit. Readiness checks belong before late-stage development or major launch spend, not after the product ships. Two patterns show up constantly:
- A clinically sound remote monitoring tool launches with no confirmed billing pathway, so revenue never materializes despite strong usage.
- A diagnostic algorithm earns technical validation but stalls in procurement because no one prepared transparency documentation buyers now expect.
Both are market readiness failures, not product failures.
Core readiness dimensions: a checklistable framework
Score each dimension with a measurable signal, not a feeling, and assign one owner who confirms it.
- Customer value and demand: a signed letter of intent or a paid pilot beats a survey. Owned by commercial leadership.
- Regulatory pathway: a clear device classification and a defined submission type, not just a hunch about exemption. Owned by regulatory affairs.
- Reimbursement and payer pathway: an existing CPT or HCPCS code paired with at least one pilot claim that was actually paid. Owned by finance and coding.
- Clinical and economic evidence: outcomes data sized to the claim you intend to market, reviewed by clinical leadership.
- Workflow and integration fit: confirmed EHR interoperability or a documented manual workaround clinicians will tolerate. Owned by product and implementation.
- Stakeholder support: a named clinical champion and at least one administrative sponsor who will defend the budget line. Owned by executive sponsor.
- Commercial model: a pricing structure payers or health systems have reacted to, not just modeled internally.
Pro Tip: Score every dimension red, yellow, or green before you write a go-to-market plan. A single red on reimbursement or regulatory pathway should stop a launch, not just slow it.
Regulatory readiness in the U.S.: classify first, plan next
The FDA describes a four-step sequence for bringing a device to market: classify the product and its controls, prepare the appropriate premarket submission, interact with the agency during review, then comply with ongoing obligations including registration and listing. Classification drives everything downstream: a 510(k) submission leans on predicate comparison and tends to move faster, a De Novo pathway applies when no predicate exists, and a PMA demands the heaviest clinical evidence and the longest timeline.
Before building a launch plan, confirm where your product falls using the FDA Digital Health Policy Navigator, which walks teams through whether a software function is likely a device at all.
Practical steps to run now:
- Draft precise intended-use language tied to the actual clinical function, not the marketing pitch.
- Run a predicate search before assuming a 510(k) applies.
- Engage FDA's Digital Health Center of Excellence or outside regulatory counsel early, not after development is locked.
For teams weighing whether a product counts as a medical device management system, our practical tactics for avoiding an unnecessary 510(k) walk through the classification questions in more depth.
Reimbursement and payer readiness: test operational assumptions, not just codes
A billing code existing is not proof that reimbursement will happen. CMS guidance on remote physiologic monitoring and telehealth sets specific operational rules: who is eligible to bill, how many days of data qualify for payment, what device and data transfer requirements apply, and what consent must be documented before a claim is valid.
CMS updates these rules on a regular cycle, and the CY 2026 Medicare Physician Fee Schedule illustrates how payment policy for remote monitoring and device-based services shifts year to year. Assumptions you validated last year may already be outdated.
Test these items inside any pilot, before scaling:
- Confirm which clinician role is eligible to bill for the service.
- Walk through the documentation workflow end to end, not just on paper.
- Verify device and data transfer meet the qualifying cadence.
- Capture consent and privacy documentation at the point of enrollment.
Interoperability and algorithm transparency: what buyers expect now
Health system buyers increasingly ask for proof, not promises, around how an algorithm works and how data moves. ONC's HTI-1 final rule raises the bar on algorithm transparency, updates certification criteria around USCDI v3, and introduces Insights Condition reporting that affects how certified health IT connects and shares data.
Prepare these artifacts before procurement conversations start, not during them:
- Decision-support documentation that explains model inputs, outputs, and intended use in plain language.
- Working FHIR endpoints that demonstrate real data exchange, not a slide describing one.
- A written update and maintenance commitment buyers can cite in their own compliance files.
Our breakdown of documents FDA reviewers want for clinical decision support maps directly onto what procurement teams now expect for algorithm transparency.
The Startup MD's rapid market readiness checklist and one-week sprint
We built a compact diagnostic matrix that healthtech leaders can run internally or hand to us as a focused engagement.
| Dimension | Quick signal to check |
|---|---|
| Customer value | Signed pilot or letter of intent exists |
| Regulatory pathway | Classification and submission type are defined |
| Reimbursement | A paid pilot claim exists, not just a code |
| Evidence | Outcomes data matches the marketing claim |
| Workflow fit | EHR integration confirmed or workaround documented |
| Stakeholder support | Named clinical champion identified |
A one-week sprint runs in this order:
- Interview the clinical champion and one skeptical stakeholder.
- Pull existing regulatory and evidence documents into one file.
- Confirm whether a pilot claim has actually been submitted and paid.
- Test the integration path against a live EHR sandbox where possible.
- Score each dimension red, yellow, or green and assign an owner to close every red.
Fractional CMO engagement can accelerate work on dimensions that stall internal teams, such as clinical evidence framing, payer conversations, and stakeholder trust, because those gaps often require clinical credibility, not just engineering.
Author perspective: decision rules for go or no-go
Three rules guide most of my go or no-go calls. First, do not scale past evidence that matches the claim you are marketing; a pilot outcome is not population-level proof. Second, require one paid payer claim before projecting reimbursement revenue, not a code lookup. Third, require one confirmed integration or workflow proof point before a multi-site rollout. A single-site pilot with a clinical champion is reasonable at low evidence maturity; a multi-state launch is not.
— Paul Bergeron MD, MBA
How The Startup MD can help: fractional CMO and advisory services
We help healthcare SaaS teams address readiness gaps through fractional Chief Medical Officer engagements and advisory services focused on clinical strategy, regulatory guidance, and payer-facing evidence. These engagements fit teams approaching a funding round, a major launch, or a stalled pilot who need clinical and commercial judgment in the room, not just a checklist. Reach out through our services page to discuss a fractional CMO or advisory engagement focused on your specific readiness gaps.
FAQ
What is market readiness?
Market readiness is the point where a product's value, evidence, regulatory status, reimbursement pathway, and workflow fit have all been validated enough to withstand real buyer scrutiny. It differs from product readiness, which only confirms the product works as designed.
What are the core dimensions to check before a healthcare product launch?
The core dimensions are customer value and demand, regulatory pathway, reimbursement and payer pathway, clinical and economic evidence, workflow and integration fit, and stakeholder support. Each needs a measurable signal and an assigned owner, not an assumption.
What regulatory pathway applies to my digital health product?
Classification determines the pathway: a 510(k) applies when a predicate device exists, a De Novo pathway applies when none does, and a PMA applies to the highest-risk devices requiring extensive clinical evidence. The FDA Digital Health Policy Navigator helps determine whether a software function is a device at all before you choose a pathway.
Why does a billing code alone not guarantee reimbursement?
A code establishes that billing is possible, but CMS remote monitoring guidance sets separate rules on eligible billing clinicians, data day-count requirements, and documentation that must all be met before a claim is actually paid. Pilots should test these operational requirements directly rather than assuming the code is sufficient.
What does ONC's HTI-1 rule require for interoperability?
ONC's HTI-1 final rule requires greater algorithm transparency, updates certification criteria including USCDI v3, and establishes Insights Condition reporting that affects how certified health IT exchanges data. Teams building AI-enabled or certified-health-IT-adjacent products should map these obligations early rather than late in development.
Sources
- How to Study and Market Your Device | FDA
- HTI-1 Final Rule - ONC
- CMS — Remote patient monitoring telehealth guidance